Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025:2965:151-178.
doi: 10.1007/978-1-0716-4742-4_5.

Generation of Lipid Nanoparticle mRNA Vaccines and Evaluation of Antigen-Specific CD8+ T-Cell Responses

Ross W Ward  1   2   3 , Aparna Ananthanarayanan  1   2   3 , Nina Bhardwaj  1   2   3 , Nicolas Vabret  4   5   6   7
Affiliations

Generation of Lipid Nanoparticle mRNA Vaccines and Evaluation of Antigen-Specific CD8+ T-Cell Responses

Ross W Ward et al. Methods Mol Biol. 2025.

Abstract

mRNA vaccines have revolutionized vaccine development against infectious diseases, as demonstrated by the rapid creation and deployment of vaccines for SARS-CoV-2. In this chapter, we present a protocol for the generation of mRNA vaccine formulations utilizing lipid nanoparticle-based delivery systems. Additionally, we provide guidance for the evaluation of (i) mRNA formulation immunogenicity, (ii) mRNA formulation induced antigen cross-presentation, and (iii) antigen-specific CD8+ T-cell responses post in vivo vaccination.

Keywords: Antigen-specific T cells; Cellular immunity; Immunogenicity; Lipid nanoparticle (LNP); Vaccine; mRNA.

PubMed Disclaimer

References

    1. Andries O et al (2015) N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 217:337–344 - PubMed
    1. Karikó K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165–175 - PubMed
    1. Hornung V et al (2010) Ligand for RIG-I. Science (80-.) 994:1–5
    1. Alameh M-G, Weissman D (2022) Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens. In: RNA therapeutics, pp 141–169. https://doi.org/10.1016/B978-0-12-821595-1.00014-2 - DOI
    1. Mu X, Greenwald E, Ahmad S, Hur S (2018) An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res 46:5239–5249 - PubMed - PMC

LinkOut - more resources